Skip to content

Advertisement

  • Poster presentation
  • Open Access

Leukemia/lymphoma development in IL-15-deficient TCR-transgenic mice

  • 1,
  • 1,
  • 2 and
  • 3
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P67

https://doi.org/10.1186/2051-1426-3-S2-P67

  • Published:

Keywords

  • Mouse Tumor
  • Test Treatment
  • Mouse Tumor Model
  • Immunocompetent Mouse
  • Tumor Frequency

Sporadic mouse tumor models are valuable tools to understand disease development and treatment efficacies. Here we show that a transgenic T cell receptor expression predisposes mice to leukemia/lymphoma development. Leukemia/lymphoma precursors expressed low amounts of MHC class I and were deleted by NK cells in immunocompetent mice resulting in increased tumor frequency under NK cell absence. Leukemias/lymphomas were clonal and regrow after transfers into NK cell-deficient hosts. Phenotypically, most leukemias/lymphomas were positive for CD3 and CD8, and all expressed high levels of the co-stimulatory molecules PD1, ICOS and CD28 as well as of CD30 resembling the phenotype of immature CD8 single-positive thymocytes. Half of the leukemias/lymphomas harbored Notch1 mutations. Dendritic cells appear to have an auxiliary role in leukemia/lymphomagenesis since their deletion caused decreased tumor growth. The study of leukemias/lymphomas in IL-15-deficient TCR-transgenic mice may help to further understand T cell lymphomagenesis, the role of lymphoma environment, and may be useful to design and test treatments.

Authors’ Affiliations

(1)
Lymphoid Malignancies, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
(2)
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
(3)
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Copyright

Advertisement